Deal Watch: Novo’s Increased Cell Therapy Commitment Includes Stem Cell Pact With BioLamina – In Vivo
In Vivo |
Deal Watch: Novo's Increased Cell Therapy Commitment Includes Stem Cell Pact With BioLamina
In Vivo Also, TapImmune merger with Marker could yield T-cell therapies that address multiple tumor-associated antigens with a better safety profile than CAR-T therapy. Bluebird and Medigene expand their TCR therapy collaboration. Already Registered? Sign in … |
